PMID- 35015332
OWN - NLM
STAT- MEDLINE
DCOM- 20220517
LR  - 20220716
IS  - 1752-8062 (Electronic)
IS  - 1752-8054 (Print)
IS  - 1752-8054 (Linking)
VI  - 15
IP  - 5
DP  - 2022 May
TI  - Proton pump inhibitor use and risk of depression and anxiety in children: 
      nationwide cohort study.
PG  - 1112-1122
LID - 10.1111/cts.13225 [doi]
AB  - Although some data have linked proton pump inhibitor (PPI) use to risk of 
      depression and anxiety, there are no studies investigating this safety issue in 
      children. This study investigated the association between PPI use and risk of 
      depression and anxiety in children. We conducted a nationwide register-based 
      cohort study in Sweden, July 1, 2007, to December 31, 2016. Following matching on 
      age and propensity score, we included 29,320 pairs of PPI initiators and 
      noninitiators among children aged 7-17 years old. The primary analysis examined 
      the risk of incident depression and anxiety, a composite outcome defined as a 
      diagnosis of depression, anxiety, or a prescription for an antidepressant. 
      Children who initiated PPI use had higher hazards for risk of depression and 
      anxiety compared with noninitiators (hazard ratios [HRs], 2.61; 95% confidence 
      interval [CI], 2.32-2.94). In analyses of the timing of depression and anxiety 
      onset after PPI initiation, the HRs were 3.71 (95% CI, 2.17-6.34) for 1-30 days, 
      3.47 (95% CI, 2.33-5.18) for 31-90 days, 2.71 (2.04-3.60) for 91-180 days, 2.52 
      (2.00-3.16) for 181-365 days, and 2.34 (1.94-2.82) for 366-730 days. Significant 
      associations were observed across all age groups. The magnitude of the 
      association increased with longer duration of PPI use (p for trend < 0.0001). The 
      association was consistent through all sensitivity analyses, including 
      high-dimensional propensity score matching (HR, 2.31, 95% CI, 2.05-2.61). PPI use 
      was associated with increased risk of depression and anxiety in children. Further 
      investigation is warranted to confirm or refute this potential association.
CI  - (c) 2022 The Authors. Clinical and Translational Science published by Wiley 
      Periodicals LLC on behalf of American Society for Clinical Pharmacology and 
      Therapeutics.
FAU - Wang, Yun-Han
AU  - Wang YH
AD  - Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska 
      Institutet, Stockholm, Sweden.
FAU - Wintzell, Viktor
AU  - Wintzell V
AD  - Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska 
      Institutet, Stockholm, Sweden.
FAU - Ludvigsson, Jonas F
AU  - Ludvigsson JF
AD  - Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska 
      Institutet, Stockholm, Sweden.
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 
      Stockholm, Sweden.
AD  - Department of Pediatrics, Orebro University Hospital, Orebro, Sweden.
AD  - Celiac Disease Center, Department of Medicine, Columbia University College of 
      Physicians and Surgeons, New York, New York, USA.
FAU - Svanstrom, Henrik
AU  - Svanstrom H
AD  - Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska 
      Institutet, Stockholm, Sweden.
AD  - Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
FAU - Pasternak, Bjorn
AU  - Pasternak B
AD  - Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska 
      Institutet, Stockholm, Sweden.
AD  - Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220119
PL  - United States
TA  - Clin Transl Sci
JT  - Clinical and translational science
JID - 101474067
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Adolescent
MH  - Anxiety/epidemiology
MH  - Child
MH  - Cohort Studies
MH  - *Depression/drug therapy/epidemiology
MH  - Humans
MH  - Propensity Score
MH  - *Proton Pump Inhibitors/adverse effects
MH  - Risk Factors
PMC - PMC9099128
COIS- Dr. Svanstrom has received consulting fees from Celgene and is employed by IQVIA, 
      outside of the submitted work. Dr. Ludvigsson coordinates, on behalf of the 
      Swedish IBD quality register (SWIBREG); a study that has received funding from 
      Janssen Corporation. All other authors declared no competing interests for this 
      work.
EDAT- 2022/01/12 06:00
MHDA- 2022/05/18 06:00
PMCR- 2022/05/01
CRDT- 2022/01/11 12:38
PHST- 2021/11/10 00:00 [revised]
PHST- 2021/09/24 00:00 [received]
PHST- 2021/09/22 00:00 [accepted]
PHST- 2022/01/12 06:00 [pubmed]
PHST- 2022/05/18 06:00 [medline]
PHST- 2022/01/11 12:38 [entrez]
PHST- 2022/05/01 00:00 [pmc-release]
AID - CTS13225 [pii]
AID - 10.1111/cts.13225 [doi]
PST - ppublish
SO  - Clin Transl Sci. 2022 May;15(5):1112-1122. doi: 10.1111/cts.13225. Epub 2022 Jan 
      19.